Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
Industry Pulse › Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
May 1, 2026 · Research
Researchers in Germany just built a single drug that hits five different receptors at once. In obese mice, it beat Ozempic. It also beat the dual-target combination behind Mounjaro. The work was published in Nature on April 30, 2026, and it points toward where the obesity drug field is heading next.
Here is what makes it interesting. Most obesity drugs work by hitting one or two targets. Semaglutide, the active ingredient in Ozempic, hits one. Tirzepatide, the active ingredient in Mounjaro, hits two. Retatrutide, the next compound in Eli Lilly’s pipeline, hits three. The German team built something that hits five. And the clever part is not the number. It is the targeting.
Why Hitting More Targets Has Been the Strategy
Obesity is not a one-receptor problem. The body has multiple overlapping systems that control hunger, fat storage, blood sugar, and energy use. If a drug only hits one of those systems, the others can compensate. The body is good at finding workarounds.
This is why the obesity drug field has been racing to combine more targets into single molecules. Each generation has produced more weight loss than the last. Semaglutide gets patients to roughly 15% body weight loss. Tirzepatide pushes that to 22%. Retatrutide, in recent Phase 3 data, hit 28.7% mean weight loss. That is the first non-surgical drug to match what bariatric surgery delivers.
The German team’s work asks the next question. If three targets is good, what about five? And how do you do it without the side effects that usually come with hitting more targets at once?
The Side Effect Problem
Adding more targets sounds good in theory. In practice it gets ugly fast. The receptors a drug hits are not just sitting in your fat cells. They are in your liver, your gut, your kidneys, your brain, your heart. Hit them all, and you get effects everywhere. Some helpful, some not.
The new drug includes a class of receptors called PPARs, which control how cells use fat and sugar. Activating PPARs is one of the most powerful metabolic levers there is. The problem is that PPAR activation everywhere in the body causes serious side effects. Drug companies have spent twenty years trying to solve this and mostly failed.
The German team solved it with a delivery trick.
How the Five-Target Drug Works
Think of the drug as having two pieces stuck together. The first piece is a peptide that binds to GLP-1 and GIP receptors, the same two receptors Mounjaro hits. The second piece is a small molecule called lanifibranor, which activates the three PPAR receptors. The two pieces are connected by a chemical link.
Here is the clever part. The link only breaks under specific conditions. When the peptide binds to a cell that has GLP-1 and GIP receptors, the cell pulls the whole drug inside. Inside the cell, the chemistry shifts and the link breaks. The PPAR-activating piece gets released, but only inside cells that already had the right receptors on the outside.
It is a delivery system. The peptide is the address. The PPAR drug is the package. The package only opens at the right address.
The result, in obese diabetic mice, was greater weight loss, less food intake, and better blood sugar control than semaglutide alone or even than the dual-target Mounjaro-like combination. And the side effects that usually come with PPAR activation were largely absent, because the PPAR drug was only being released in cells that needed it.
What the Mouse Data Showed
The team tested the drug in obese diabetic mice and ran a series of experiments to confirm the mechanism. They knocked out individual receptors in mice to see which ones the drug needed. The effect weakened when GLP-1, GIP, or PPARδ receptors were blocked. The effect disappeared entirely when both GLP-1 and GIP receptors were knocked out together.
That pattern matters. It tells you the drug is actually doing what the design says it should be doing. It is not working through some unexpected pathway. The peptide handle is what gets it into the right cells, and removing that handle removes the effect.
The Translational Caveat
Mice are not humans. This is the standard caveat with every obesity drug discovery story, and it is genuinely important.
Mouse obesity models tend to amplify drug effects compared to what shows up in human trials. A drug that produces dramatic weight loss in mice often shows more modest effects in people. Durability after stopping the drug is another translational gap. Mice tested for a few weeks may not show the receptor adaptation that emerges in humans over months.
Independent commentators flagged this. Chun-Xia Yi, a neuroscientist at UMC Amsterdam, called the design creative but noted that mouse efficacy signals routinely overstate human outcomes. Li Qiang, a pharmacologist at Peking University, told C&EN the work sets a new benchmark while emphasizing that benchmarks set in mice still have to clear human trials.
The realistic timeline from a Nature paper like this to an FDA-approved drug, if everything goes right, is roughly seven to ten years. This is exciting science, not a near-term clinical option.
What This Signals for the Field
Two things stand out about the May 1 publication.
First, this is not a one-off. Lilly-funded researchers are reportedly preparing to present preclinical data on a different five-target drug at a conference in June. That one combines GLP-1, GIP, and glucagon receptors with two additional targets called amylin and calcitonin. If both the German and the Lilly approaches advance, the obesity drug field will move past triple agonism within a single product cycle. The benchmark for next-generation obesity drugs is shifting from “how many receptors” to “how cleanly can you target them.”
Second, the delivery strategy is portable. Using a peptide as the address label for a drug payload is not a new idea, but applying it to obesity therapeutics at this scale is. Other compounds that have been hard to develop because of widespread side effects could potentially be rescued the same way. The peptide-as-handle approach is a tool, not just a one-off design.
What This Means for Research Peptides
For laboratories working with the incretin family, the immediate takeaway is methodological. Studies of GLP-1, GIP, and combination peptides will increasingly need to account for cross-target signaling and downstream nuclear receptor effects. Treating these compounds as simple receptor agonists understates their pharmacology.
The German work also opens an experimental design space worth tracking. Incretin peptides can serve as cell-targeting moieties for non-peptide payloads. Laboratories studying receptor-mediated delivery, peptide conjugates, or targeted activation strategies have a new template to work with. For broader context on the compounds in this category, see Metabolic Peptide Research.
For laboratory research applications studying triple-agonist incretin pharmacology, research-grade Retatrutide is available with batch-specific Certificate of Analysis and 99%+ purity confirmation by HPLC and mass spectrometry, documented for in vitro and non-clinical research use only.
What to Watch Next
Three things over the next 12 months.
The Lilly five-target preclinical data due in June. If it shows similar improvements over current dual and triple agonists, the field consolidates around five-target as the new ceiling.
The next phase of the German team’s work. Mouse data is the start. Primate studies and early human work will determine whether the targeting strategy holds at clinical exposures.
Whether other developers adopt the peptide-as-handle approach for compounds outside the incretin family. The strategy could move into other therapeutic areas where systemic side effects have blocked development.
The bigger picture is that the obesity drug field is moving fast and getting more sophisticated. The drugs in pharmacies today are already a generation behind what is in Phase 3. The drugs in Phase 3 are a generation behind what is in preclinical labs. The German team’s work is the front of that wave.
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
Researchers in Germany just built a single drug that hits five different receptors at once. In obese mice, it beat Ozempic. It also beat the dual-target combination behind Mounjaro. The work was published in Nature on April 30, 2026, and it points toward where the obesity drug field is heading next.
Here is what makes it interesting. Most obesity drugs work by hitting one or two targets. Semaglutide, the active ingredient in Ozempic, hits one. Tirzepatide, the active ingredient in Mounjaro, hits two. Retatrutide, the next compound in Eli Lilly’s pipeline, hits three. The German team built something that hits five. And the clever part is not the number. It is the targeting.
Why Hitting More Targets Has Been the Strategy
Obesity is not a one-receptor problem. The body has multiple overlapping systems that control hunger, fat storage, blood sugar, and energy use. If a drug only hits one of those systems, the others can compensate. The body is good at finding workarounds.
This is why the obesity drug field has been racing to combine more targets into single molecules. Each generation has produced more weight loss than the last. Semaglutide gets patients to roughly 15% body weight loss. Tirzepatide pushes that to 22%. Retatrutide, in recent Phase 3 data, hit 28.7% mean weight loss. That is the first non-surgical drug to match what bariatric surgery delivers.
The German team’s work asks the next question. If three targets is good, what about five? And how do you do it without the side effects that usually come with hitting more targets at once?
The Side Effect Problem
Adding more targets sounds good in theory. In practice it gets ugly fast. The receptors a drug hits are not just sitting in your fat cells. They are in your liver, your gut, your kidneys, your brain, your heart. Hit them all, and you get effects everywhere. Some helpful, some not.
The new drug includes a class of receptors called PPARs, which control how cells use fat and sugar. Activating PPARs is one of the most powerful metabolic levers there is. The problem is that PPAR activation everywhere in the body causes serious side effects. Drug companies have spent twenty years trying to solve this and mostly failed.
The German team solved it with a delivery trick.
How the Five-Target Drug Works
Think of the drug as having two pieces stuck together. The first piece is a peptide that binds to GLP-1 and GIP receptors, the same two receptors Mounjaro hits. The second piece is a small molecule called lanifibranor, which activates the three PPAR receptors. The two pieces are connected by a chemical link.
Here is the clever part. The link only breaks under specific conditions. When the peptide binds to a cell that has GLP-1 and GIP receptors, the cell pulls the whole drug inside. Inside the cell, the chemistry shifts and the link breaks. The PPAR-activating piece gets released, but only inside cells that already had the right receptors on the outside.
It is a delivery system. The peptide is the address. The PPAR drug is the package. The package only opens at the right address.
The result, in obese diabetic mice, was greater weight loss, less food intake, and better blood sugar control than semaglutide alone or even than the dual-target Mounjaro-like combination. And the side effects that usually come with PPAR activation were largely absent, because the PPAR drug was only being released in cells that needed it.
What the Mouse Data Showed
The team tested the drug in obese diabetic mice and ran a series of experiments to confirm the mechanism. They knocked out individual receptors in mice to see which ones the drug needed. The effect weakened when GLP-1, GIP, or PPARδ receptors were blocked. The effect disappeared entirely when both GLP-1 and GIP receptors were knocked out together.
That pattern matters. It tells you the drug is actually doing what the design says it should be doing. It is not working through some unexpected pathway. The peptide handle is what gets it into the right cells, and removing that handle removes the effect.
The Translational Caveat
Mice are not humans. This is the standard caveat with every obesity drug discovery story, and it is genuinely important.
Mouse obesity models tend to amplify drug effects compared to what shows up in human trials. A drug that produces dramatic weight loss in mice often shows more modest effects in people. Durability after stopping the drug is another translational gap. Mice tested for a few weeks may not show the receptor adaptation that emerges in humans over months.
Independent commentators flagged this. Chun-Xia Yi, a neuroscientist at UMC Amsterdam, called the design creative but noted that mouse efficacy signals routinely overstate human outcomes. Li Qiang, a pharmacologist at Peking University, told C&EN the work sets a new benchmark while emphasizing that benchmarks set in mice still have to clear human trials.
The realistic timeline from a Nature paper like this to an FDA-approved drug, if everything goes right, is roughly seven to ten years. This is exciting science, not a near-term clinical option.
What This Signals for the Field
Two things stand out about the May 1 publication.
First, this is not a one-off. Lilly-funded researchers are reportedly preparing to present preclinical data on a different five-target drug at a conference in June. That one combines GLP-1, GIP, and glucagon receptors with two additional targets called amylin and calcitonin. If both the German and the Lilly approaches advance, the obesity drug field will move past triple agonism within a single product cycle. The benchmark for next-generation obesity drugs is shifting from “how many receptors” to “how cleanly can you target them.”
Second, the delivery strategy is portable. Using a peptide as the address label for a drug payload is not a new idea, but applying it to obesity therapeutics at this scale is. Other compounds that have been hard to develop because of widespread side effects could potentially be rescued the same way. The peptide-as-handle approach is a tool, not just a one-off design.
What This Means for Research Peptides
For laboratories working with the incretin family, the immediate takeaway is methodological. Studies of GLP-1, GIP, and combination peptides will increasingly need to account for cross-target signaling and downstream nuclear receptor effects. Treating these compounds as simple receptor agonists understates their pharmacology.
The German work also opens an experimental design space worth tracking. Incretin peptides can serve as cell-targeting moieties for non-peptide payloads. Laboratories studying receptor-mediated delivery, peptide conjugates, or targeted activation strategies have a new template to work with. For broader context on the compounds in this category, see Metabolic Peptide Research.
For laboratory research applications studying triple-agonist incretin pharmacology, research-grade Retatrutide is available with batch-specific Certificate of Analysis and 99%+ purity confirmation by HPLC and mass spectrometry, documented for in vitro and non-clinical research use only.
What to Watch Next
Three things over the next 12 months.
The Lilly five-target preclinical data due in June. If it shows similar improvements over current dual and triple agonists, the field consolidates around five-target as the new ceiling.
The next phase of the German team’s work. Mouse data is the start. Primate studies and early human work will determine whether the targeting strategy holds at clinical exposures.
Whether other developers adopt the peptide-as-handle approach for compounds outside the incretin family. The strategy could move into other therapeutic areas where systemic side effects have blocked development.
The bigger picture is that the obesity drug field is moving fast and getting more sophisticated. The drugs in pharmacies today are already a generation behind what is in Phase 3. The drugs in Phase 3 are a generation behind what is in preclinical labs. The German team’s work is the front of that wave.